The nanoparticles were preferentially taken up into EGFR+ cancer cells (MDA-MB-468, BT-549, MDA-MB-231) over cells that were EGFR- (KPL4, MCF7), as analyzed by flow cytometry (Figure 4). The gene discussed is EGFR; the disease is cancer.